Browse Articles

Discover research articles across all indexed journals

A phase II clinical study of camrelizumab plus apatinib in combination with stereotactic body radiotherapy (SBRT) for advanced non-clear cell renal cell carcinoma (nccRCC).

Journal of Clinical Oncology Xinyue Zhang, Ruiqi Liu, Yang Liu et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.557

557 Background: The efficacy of targeted therapy alone in the treatment of advanced nccRCC remains unsatisfactory, but its combination with immunotherapy and/or SBRT is worth exploring. In this study, we aimed to investigate the safety and efficacy of camrelizumab plus apatinib combined with SBRT for advanced nccRCC. Methods: This is a single-arm, phase Ⅱ study enrolling recurrent/metastatic nccRCC patients (pts), for whom the cytoreductive SBRT (defined as the lesions receiving SBRT≥50% of the tumor burden) can be safety applied (ChiCTR2000034727). No liver or brain metastasis was allowed. Eligible pts received camrelizumab (200mg, day 1) (for wgt <= 40kg, 3mg/kg) and apatinib (250mg, once daily, day 1-14) in a 2-week cycle. Cytoreductive SBRT (20-45 Gy, 1-5 fractions) was performed between the 1 st and the 3 rd administration of camrelizumab. The primary endpoint of this study was the objective response rate (ORR); secondary endpoints were progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of response (DOR), safety, and quality of life. Results: From Oct. 26, 2020, and Sep. 6, 2024, a total of 37 pts were enrolled, and 32 pts were evaluable for efficacy after SBRT. Among them, 11 (34.4%) had Xp11.2 translocation, 10 (31.3%) pts had papillary, 5 (15.6%) had fumarate hydratase-deficient, 2 (6.3%) had chromophobe, 1 (3.1%) had collecting duct, 1 (3.1%) had sarcomatoid, and 2 (6.3%) had unclassified histology. 3 (9.4%) pts were local-reginal recurrent, whereas 14 (43.8%) were oligometastatic, and 15 (46.9%) were multiple metastatic. 31 (96.9%) pts were IMDC intermediate or high risk, and 10 (31.3%) pts received at least one prior systemic therapy. With a median follow-up time of 18.9 months, 23 (71.9%) pts achieved ORR, of which 12 (37.5%) pts had complete response and 11 (34.4%) pts had partial response. The DCR was 93.8%, and the median PFS was 19.0 months. The most common adverse events (AEs) of any grade were creatinine increased (n = 21, 65.6%), followed by anemia (n = 19, 59.4%), aspartate aminotransferase (AST) increased (n = 19, 59.4%), proteinuria (n = 19, 59.4%), and hypertension (n = 13; 40.6%). Grade 3 AEs occurred in 11 pts (4 proteinuria, 4 AST increased, 2 blood bilirubin increased, 2 rash, and 2 neutrophil counts decreased). The most common AEs after SBRT were nausea (n = 10; 31.3%). No grade 4-5 AEs occurred. Furthermore, the proportion of CD4+ and CD8+ lymphocytes in peripheral blood increased after SBRT and dropped to baseline levels after the 4 th and the 8 th cycle of camrelizumab, respectively. To the opposite, the proportion of CD19+ lymphocytes decreased after SBRT but continued to increase after the 2 nd circle of camrelizumab. Conclusions: Camrelizumab plus apatinib combined with SBRT showed promising antitumor activity and manageable toxicity in pts with recurrent/metastatic nccRCC. Clinical trial information: ChiCTR2000034727 .

Management of relapsed primary retroperitoneal (RP) germ-cell tumor (GCT) after front-line chemotherapy.

Journal of Clinical Oncology Kirsten Lewis, Rebecca Hassoun, Sandra K. Althouse et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.637

637 Background: Primary RP GCT represents a rare subset of extragonadal GCTs. While front-line therapy remains similar to gonadal GCT, there is limited data on management of relapsed disease for these patients (pts). Here, we describe management and outcomes of pts with relapsed primary RP GCT. Methods: The prospectively maintained Indiana University testicular cancer database was queried for patients with primary RP GCT who relapsed after first-line therapy between 1990-2024. Kaplan-Meier method was used to analyze progression free survival (PFS) and overall survival (OS). Survival outcomes based on type of second-line chemotherapy was compared using the log rank test. Results: 53 pts were included in the analysis. Median age at diagnosis was 33.7yrs (17.4-67.9). Primary tumor pathology was non-seminoma in 75.5% and seminoma in 24.5%. Predominant histology was seminoma (30.2%), mixed (26.4%), choriocarcinoma (17.0%), yolk sac tumor (13.2%), embryonal (9.4%), teratoma (3.8%). Other metastasis sites included pulmonary (56.6%), liver (35.9%), posterior mediastinum (15.1%), pelvic lymph nodes (13.2%), brain (13.2%), bone (9.4%). IGCCCG risk was good in 30.2%, intermediate in 15.1%, and poor in 54.7%. First-line chemo was BEPx4 (54.6%), VIPx4 (11.3%), BEP x3 (7.5%), EPx4 (7.6%), BEPx2 + HDCTx2 (2.0%), and other (17.0%). All 53 pts had progression of disease after first-line chemo. 44 received salvage chemotherapy, 5 received RPLND, 2 other salvage surgery, 1 radiation, and 2 received no salvage therapy. Salvage chemo was HDCT for 69.8% vs. standard salvage chemo for 30.2%. For pts treated with HDCT, 83% completed 2 cycles. 46.7% of those treated with HDCT progressed afterward. Of pts who had salvage RPLND, 3 were found to have teratoma and 2 had active GCT. 2 pts had other salvage surgery; 1 had thoracotomy with GCT and 1 had craniotomy with GCT. At time of last follow-up, 28.3% of all pts were alive with NED, 11.3% were alive with disease, 13.2% were lost to follow-up, and 47.2% had died of disease. The table lists PFS and OS by salvage chemo type. Conclusions: Patients with relapsed primary RP GCT seem to have worse outcomes compared with historical results from relapsed gonadal GCT. A subset of patients with relapsed primary RP GCT are curable with salvage therapy. Survival outcomes by salvage chemotherapy received. HDCT N=30 Standard dose chemo N= 14 p-value 2-yr PFS 47.7% (95% 28.7-64.5) 31.8% (95% 7.7-59.9) p=0.18 2yr OS 53.8% (95% 34.0-70.0) 68.6 (95% 30.5-88.7) p=0.84

Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: A randomized phase II trial (GROUQ-PCS 9).

Journal of Clinical Oncology Tamim Niazi, Fred Saad, Rashmi Koul et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.22

22 Background: Metastases directed therapy (MDT) in metachronous hormone sensitive prostate cancer (mHSPS) patients has been shown to delay systemic therapy and to a lesser extent improve oncological outcome. To date there has not been strong data to suggest benefit of MDT in castration resistant prostate cancer (CRPC). In this multi-centric randomized phase II trial, we sought to determine the benefit of stereotactic body radiotherapy (SBRT) in oligometastatic CRPC (omCRPC) patients. Methods: PCS-9 was originally designed as an adaptive randomized phase II/III trial conducted across 13 sites in Canada. Given that ARPIs became the standard of care in mHSPC, the study was stopped at the phase II level after 100 mCRPC patients, with 5 or less metastatic sites, were recruited. Patients were randomly assigned in a 1:1 ratio to androgen deprivation therapy (ADT) + enzalutamide (Enza), arm-1 or ADT + Enza + SBRT to the conventionally (CT/MRI/bone scan) identified oligometastatic sites, arm-2. The primary endpoint was radiological progression free survival (rPFS), defined as radiological progression or death from any cause. Results: Of the 100 omCRPC patients, 48 were randomized to ADT+Enza and 52 to ADT+Enza+SBRT. There was no difference in patient or disease characteristics. One to three metastases occurred in 89.6% of arm-1 and 84.6% of arm-2, while visceral involvement accounted for 2.1 and 5.8%, respectively. The addition of SBRT doubled the median rPFS compared to ADT and Enza alone. rPFS was 4.6 years in the SBRT group and 2.3 years in the ADT and Enza arm, a 50% risk reduction (HR: 0.5 with 95% CI, 0.28-0.88; p=0.017). Similarly, biochemical progression free survival (bPFS) was 4.5 years for the SBRT arm and 2.6 years for ADT and Enza alone arm, a 44% risk reduction (HR:0.56 95% CI, 0.31-0.99 p=0.0425). At the time of this analysis there was a 27% risk reduction of death with the addition of SBRT (HR:0.73; 95% CI, 0.33-1.64; p=0.463), however the median OS had not been reached for either arm. Time to subsequent therapy was significantly delayed by the addition of SBRT. The median time to subsequent therapy was 5.1 years for the SBRT arm vs. 3.8 years for the ADT + Enza alone arm, a risk reduction of 48% (HR:0.52; 95% CI, 0.27-0.047; p:0.047). There was no difference in adverse event between the arms including fatigue, hypertension and fracture. Only 4 patients in the SBRT arm reported transient pain flare at the SBRT site and one patient had acute asymptomatic pneumonitis. Conclusions: The addition of SBRT to oligometastatic sites in mCRPC significantly improved rPFS, improved bPFS and delayed the time to next line of therapy. Although OS remains immature, there was numerical reduction in the risk of death. These results strongly suggest that SBRT to oligometastatic sites is beneficial and should be considered in patients with oligo-metastatic CRPC. Clinical trial information: NCT02685397 .

Application of ML models to predict postoperative outcomes in renal cell carcinoma.

Journal of Clinical Oncology Atulya Aman Khosla, Mohammad Arfat Ganiyani, Manas Vaibhav Pustake et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.463

463 Background: Accurately predicting postoperative outcomes, such as major and minor complications, readmissions, and mortality, enables personalized preoperative planning, informed decision-making, and improved perioperative management. In this study, we utilized a machine learning (ML) model to predict these outcomes in RCC patients undergoing nephroureterectomy, radical nephrectomy, partial nephrectomy, and other excision procedures on the kidney using data from the National Surgical Quality Improvement Program (NSQIP; 2016-2021). Methods: A gradient-boosted tree (GBT) model was developed and trained to predict the primary outcomes of interest: major complications, minor complications, 30-day readmission, and mortality. The NSQIP dataset provided a robust source of patient data, encompassing a wide array of variables, including demographic information, preoperative health status, comorbidities, intraoperative factors, and postoperative laboratory results. The model's performance was rigorously evaluated using various measures, such as AUROC, generalized R-square, MIS classification rate, etc. The model's predictions were validated using separate training (70%) and validation (30%) cohorts to ensure generalizability and applicability in diverse patient populations. Results: In the analysis, 36,284 cases were included. The GBT model demonstrated substantial predictive power across all four outcomes. In predicting mortality, the model achieved an AUROC of 0.98 in the training and 0.80 in the validation set, with a misclassification rate of 0.68%. The prediction of major complications was also robust, with AUROC of 0.94 in the training set and 0.91 in the validation set, accompanied by a misclassification rate of 2.2%. Similarly, the model's performance in predicting minor complications and 30-day readmissions was strong, with AUROC values of 0.70 and 0.66, respectively, in the validation sets. Among the most influential predictors identified by the model were age, diabetes, sepsis, bleeding disorders, ASA classification, and preoperative albumin levels. These factors consistently contributed to the model's accuracy across the different outcome measures. BMI was among the top 15 predictors for all four outcomes in GBT analysis. Conclusions: Our study demonstrated that using a national registry, ML models can accurately predict postop outcomes among patients with RCC. By integrating a wide range of patient-specific variables, the model offers a powerful tool for clinicians to identify high-risk patients and tailor perioperative care accordingly. These findings support broader ML adoption in surgical decision-making to enhance patient safety and optimize outcomes. Post-op complications in RCC by BMI category. BMI<30 BMI≥30 p-value Mortality 115 (0.64) 98 (0.54) 0.22 Major 580 (3.21) 607 (3.33) 0.49 Minor 798 (4.41) 998 (5.48) <0.0001 30-Day Readmission 1055 (5.83) 1045 (5.74) 0.70

A clinical trial evaluating the efficacy and safety of disitamab vedotin plus tislelizumab combined with re-TURBT in the treatment of HER-2-high expression (2+-3+) non-muscle invasive bladder cancer at high-risk and very high-risk.

Journal of Clinical Oncology Jianhui Chen, Yiming Su, Rong Liu et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps895

TPS895 Background: Current studies indicate that the combination of Disitamab Vedotin and PD-1 inhibitors can enhance the efficacy of systemic therapy in patients with HER2-positive urothelial carcinoma, with an acceptable safety profile. However, the evidence supporting its use in high-risk and very high-risk NMIBC remains limited. And several clinical guidelines recommend a re-TURBT for high-risk NMIBC patients, as it has been shown to significantly reduce the 5-year recurrence and progression rates.Therefore, this study aims to evaluate the efficacy and safety of the triplet regimen of Disitamab Vedotin, Tislelizumab (a PD-1 inhibitor), and re-TURBT in patients with HER2 IHC 2+ or 3+ high-risk and very high-risk NMIBC. Methods: Patients diagnosed with high-risk and very high-risk NMIBC, based on medical history, clinical presentation, imaging examinations (such as MRI with plain and enhanced scanning), and transurethral resection for tissue pathological biopsy, are included in the "case screening process".After excluding surgical contraindications, TURBT is performed; postoperative tissue pathological examination confirms NMIBC, and patients with immunohistochemical results of HER2 as 3+ or 2+ enter further screening. Referring to the AUA guidelines, high-risk and very high-risk NMIBC are included in subsequent analysis, where those who meet the inclusion criteria of this study, excluding the exclusion criteria, and who have recovered well after the initial TURBt and are assessed to be able to complete a second TURBT within six weeks are considered as the final candidates for enrollment.Eligible patients for single-arm enrollment (N=40) will receive Tislelizumab (200mg) + Disitamab Vedotin (120mg for weight ≤60Kg or 2.0mg/Kg for weight ≥60Kg) the day after the initial TURBT, to be repeated every 3 weeks (Q3W). Patients are also scheduled to undergo a second TURBT within 6 weeks, and after the surgery, they will continue with three more courses of Tislelizumab + Disitamab Vedotin (Q3W) until the end of the 3-year follow-up period. The primary endpoint for evaluation in this study phase is the 1-year event-free survival rate (EFS),which is defined as the possibility of patients have not experienced any events for at least 12 months after receiving treatment, including death, disease progression, switch to chemotherapy, addition of other treatments, fatal or intolerable side effects, etc. Clinical trial information: NCT06630871 .

A phase I/II study of neoadjuvant, intra-arterial administration of (177Lu)lutetium vipivotide tetraxetan in subjects with high-risk, localised or locally advanced prostate cancer (LUPUS).

Journal of Clinical Oncology Claudia Kesch, Volker Meyer, Christine Praus et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps431

TPS431 Background: The recent LuTectomy trial suggested that intra-venous [177Lu]Lu-PSMA-617 prior to surgery in men with high-risk localised or locally advanced prostate cancer (HRCaP) is safe and effective. We hypothesise that intra-arterial infusion will further enhance target lesion uptake and efficacy without compromising safety. LUPUS is the first trial investigating (177Lu)Lutetium vipivotide tetraxetan intra-arterial infusion and will help to further evaluate if there is a role for neoadjuvant radioligand therapy in HRCaP. Methods: Phase I/II study of neoadjuvant, pre-surgical (177Lu)Lutetium vipivotide tetraxetan as intra-arterial infusion in men with HRCaP who are candidates for radical prostatectomy (EU CTR 2022-500838-28-00). Intra-arterial perfusion is performed via a catheter into A. iliaca interna without concomitant embolization. In the first cohort, 10 patients will receive one cycle of 200 mCi (7.4 GBq) (177Lu)Lutetium vipivotide tetraxetan followed by radical prostatectomy 6 weeks thereafter. If less than 4 out of 10 patients have to delay surgery or suffer from CTCAE Grade ≥3 adverse events (AEs) due to the treatment, 10 additional patients will be included and receive one cycle of 400 mCi (14.8 GBq) (177Lu)Lutetium vipivotide tetraxetan. Enrolment began in September 2024. Primary endpoints are AEs and days of delay of scheduled surgery related to intra-arterial (177Lu)Lutetium vipivotide tetraxetan therapy. Secondary endpoints are PSA-response and pathological response. Other endpoints include imaging changes, changes in quality of life and dosimetry. Clinical trial information: EU Clinical Trial no.: 2022-500838-28-00 .

PPARG protein expression in advanced urothelial carcinoma and selection for response to FX-909, a first-in-class PPARG-targeting agent.

Journal of Clinical Oncology Evisa Gjini, William Motley, Adarsh Joshi et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.856

856 Background: FX-909, a PPARG inverse agonist, is being evaluated in a first-in-human, dose escalation and expansion study in patients with advanced urothelial carcinoma (UC; NCT05929235). PPARG drives development of UC and its expression is associated with the luminal lineage, which accounts for ~65% of all advanced UC patients 2 . An IHC prototype assay was developed to detect PPARG expression in formalin-fixed paraffin-embedded UC tissues. Our data show that PPARG protein expression correlated with PPARG RNA expression in a retrospective cohort of archival tissue from high-grade localized UC. Methods: Commercial antibodies, clones C26H12, K.242.9 and E-8, were tested and validated using UC and control normal tissues. The E-8 clone was selected for further development based on demonstration of good specificity, sensitivity, range, and linearity. Specificity of the PPARG staining was demonstrated in cell lysates, where PPARG expression level was confirmed by Western blot (HEK293, BC3C, UMUC9, and RT112). Assay performance was evaluated in a cohort of 25 high-grade localized, stage III-IV UC patient samples. Semi-quantitative analysis [percent (%) tumor score and H-score] was conducted by a pathologist. Gene expression values from RNAseq were normalized by transcripts-per-million (TPM). Molecular classification was performed using non-negative matrix factorization rank 5 following the Robertson method 3 derived from RNAseq. Results: The E-8 clone detected a broad range of PPARG expression, with a predominantly nuclear staining pattern at staining intensities from 0 to +3. Each sample exhibited different staining intensities, highlighting the heterogeneity of PPARG expression. Eighty-eight percent of cases showed PPARG expression in more than 50% of their tumor cells (22 out of 25). H-scores varied from 0 to 270 (Median H-Score = 146), where 64% of the cases showed a moderate PPARG expression with H-scores ranging between 100 and 200. PPARG protein expression quantitated based upon the % tumor area with 2+ or greater staining correlated with RNA expression levels (Spearman correlation coefficient r = 0.66; p-value <0.01). Similarly to previous data 2,5 , 52% of the cases in this cohort were of luminal lineage. The median RNA expression level of PPARG was significantly higher in the luminal subgroup compared to the non-luminal subgroup (6.0 Log2[TPM+1] vs 3.53 Log2[TPM+1], p <0.01). Conclusions: These data show the IHC assay is sensitive and specific for the detection of PPARG expression in advanced UC with utility to identify patients with potential to respond to FX-909, a first-in-class PPARG-targeting agent 4 . 1. Sims R, AACR 2023, Fl; 2. Motley W, et al. EORTC 2022; 3. Robertson AG, et al. Cell 2017; 4. Iyer G, et al. ASCO GU 2024, CA; 5. Kirov S, AACR-NCI-EORTC 2023, MA.

Predicting long term outcomes following radical prostatectomy using a validated pathology-based multimodal artificial intelligence biomarker.

Journal of Clinical Oncology Matthew R. Cooperberg, Kevin Shee, Janet E Cowan et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.364

364 Background: Over the past decade, multiple biomarkers have been developed and validated to improve precision of prostate cancer prognosis estimation. However, these require access to archival tissue and central laboratory processing for RNA extraction, and as a result are labor-intensive and expensive. Deep learning models based on image analysis of standard clinical pathology slides may offer similar accuracy with much improved access and lower cost. Multimodal artificial intelligence (MMAI) models (Artera, Los Altos, CA) have previously been validated to prognosticate as well as predict response to intensified treatment among patients undergoing radiation therapy and have been endorsed in the NCCN prostate cancer guidelines. We determined the accuracy of an MMAI model in prognosticating outcomes after radical prostatectomy (RP) using tissue microarray (TMA) specimens. Methods: We previously built a TMA from 424 mostly low- to intermediate-risk RP cases with rich clinical annotation and long-term follow-up. We scanned this TMA at high resolution and determined MMAI (scored 0 to 1) and Cancer of the Prostate Risk Assessment post-Surgical (CAPRA-S, scored 0-12) scores. We performed logistic regression to determine the MMAI’s score association with adverse pathology (pT≥3a and/or grade group ≥3), and Cox proportional hazards regression to determine the independent ability of the MMAI score to predict biochemical recurrence (two PSA tests ≥0.2 ng/ml or any second treatment) and metastasis after RP. Odds ratios (OR) and hazard ratios (HR) were determined per 0.1 increase in MMAI score. Results: The TMA was successfully segmented and images and MMAI scores were able to be generated for 414 (98%) of cases. Median (IQR) follow-up was 13.2 (7.8-18.3) years. By CAPRA-S, 273 (66%), 114 (28%), and 24 (6%) were low (0-2), intermediate (3-5), and high (≥6) risk, respectively. Recurrence-free and metastasis-free survival were 74% and 96% at 10 years, respectively. Median (IQR) MMAI risk scores were 0.25 (0.18-0.33). On logistic regression, the MMAI score was significantly associated with risk of adverse pathology (OR: 1.05, 95% CI 1.03-1.07, p<0.01). On Cox regression adjusting for CAPRA-S, MMAI risk score was significantly associated with risk of both recurrence (HR 1.04, 95% CI 1.02-1.06, p<0.01) and metastasis (HR 1.05, 95% CI 1.02-1.07, p<0.01). Conclusions: In this cohort of largely lower-risk RP patients, the MMAI score derived from RP TMA samples —originally developed among radiation therapy patients on prostate biopsy samples—adds independent prognostic information above a well-validated multivariable clinical risk model. The MMAI platform allows for rapid, non-destructive analysis of standard pathology slides and should compare favorably to RNA-based platforms in terms of access, speed, and cost.

A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with <i>FGFR3</i> alterations: Initial results from FORAGER-1.

Journal of Clinical Oncology Gopa Iyer, Hiromichi Ebi, Natalie Cook et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.662

662 Background: Activating alterations in FGFR3 (most commonly S249C) occur in 15-20% of metastatic urothelial cancers (mUC) and &lt;5% in other solid tumors. Erdafitinib, a pan FGFR1-4 inhibitor, improves survival in 2L FGFR3 -altered mUC but has dose limiting toxicities (DLTs) driven by off-target FGFR1/2/4 inhibition. LY3866288 is an oral, potent, isoform-selective, small molecule FGFR3i designed to limit off-target toxicities with preserved activity against acquired FGFR3 resistance mutations. Here we report initial clinical data from the phase 1 dose escalation cohort of LY3866288in FGFR3 -altered advanced solid tumors. Methods: Adults with advanced or metastatic solid tumors with an FGFR3 or FGFR3 ligand alteration (tumor or blood) that progressed on available standard therapies, ECOG PS ≤1, and RECIST v1.1 evaluable (including non-measurable) disease were eligible. Dose escalation used a single-patient accelerated design followed by mTPI-2 method. Key endpoints were safety, PK, and antitumor activity. Serial plasma samples were collected for ctDNA analysis. Results: As of 27 Aug 2024, 101 patients (pts) were treated at 10 dose levels (DLs) of LY3866288 (6 mg QD – 400 mg BID). Median age was 67 (range, 26-93), 69% ECOG PS 1, and 70% had mUC. Median lines of prior therapy was 3 (range, 1-9), including prior FGFRi in 23%. LY3866288 consistently demonstrated trough concentrations that exceeded IC 90 for FGFR3 S249C at DLs ≥200 mg BID. No significant differences in exposures were observed in pts with moderate renal insufficiency (eGFR 30-49 ml/min). No DLT was observed at any DL. At DLs ≥200 mg BID, the most common treatment-emergent AEs (TEAEs) were diarrhea (67%), hyperphosphatemia (28%), fatigue (23%), increased ALT (22%), and AST (22%); most (68%) TEAEs were grade 1/2. TEAEs associated with poor tolerance and compliance to erdafitinib (retinopathy, onycholysis, and hand-foot syndrome) were ≤5% and low grade. Treatment-related AEs (TRAEs) led to dose reduction in 5% of pts and none were associated with discontinuation. In mUC pts with an activating mutation/fusion dosed at ≥200 mg BID, the objective response rate (ORR) was 42% (14/33; 10 confirmed as of 6 Sep 2024, 4 ongoing and pending confirmation); responses were observed in both mutations (Y373C, S249C, R248C, S371C) and fusions (TACC3). In mUC pts previously treated with an FGFRi, the ORR was 45% (5/11). One pt each with NSCLC (S249C) and biliary tract cancer (TACC3) also achieved a PR. 14/16 PRs (88%) are ongoing. Decreases in FGFR3 ctDNA VAF occurred in 12/13 pts (92%) with available results at cycle 2 or 3, of which 8 achieved clearance (5 with PR; 3 with SD). Conclusions: LY3866288 is well-tolerated with robust clinical activity at multiple DLs, including in erdafitinib refractory mUC. Randomized dose optimization is ongoing and updated results will be presented. Clinical trial information: NCT05614739 .

PSMA PET vs. pelvic MRI in biochemically recurrent prostate cancer.

Journal of Clinical Oncology Ida Sonni, Vishnu Murthy, Raj Mehta et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.40

40 Background: After primary definitive therapy of localized prostate cancer with either radical prostatectomy or radiation therapy, up to 50% of patients will experience biochemical recurrence (BCR) of disease. The objective of this descriptive, retrospective analysis is to compare the performance of PSMA PET/CT and pelvic MRI in BCR and investigate the added value of their combined use in this patient population. Methods: Patients with BCR who underwent PSMA PET/CT and pelvic MRI within three months of each other at the University of California, Los Angeles with available imaging and follow-up data were included in our retrospective analysis. Two board-certified nuclear medicine physicians blinded to clinical information interpreted the PSMA PET/CT scans independently and described up to three positive findings. A third nuclear medicine physician resolved any disagreements (2:1 majority rule). In a similar framework, two radiologists interpreted the pelvic MRIs with a third radiologist serving as a tiebreaker. For patients with metastatic disease, PSMA PET/CT scans were interpreted according to PROMISE criteria. Data on disagreements between clinical PSMA PET/CT and pelvic MRI reads, disagreements between blinded and clinical PSMA PET/CT and pelvic MRI reads, and subsequent management based on findings from clinical PSMA PET/CT and pelvic MRI were collected. Results: 101 patients were included in this retrospective analysis, of which 84 (83%) had localized BCR and 17 (17%) had metastatic BCR. 10/84 (12%) patients with localized BCR had a negative clinical pelvic MRI and positive PSMA PET/CT, with 33% of these lesions noted to be in the lymph nodes, while 8/84 (10%) patients had a negative clinical PSMA PET/CT and positive pelvic MRI, with 100% of these lesions noted to be in the prostate or prostate bed. 12/17 (71%) patients with metastatic BCR had a positive clinical PSMA PET/CT and negative pelvic MRI. In 10/84 (12%) patients with localized BCR, the blinded PSMA PET/CT reads were negative while the clinical PSMA PET/CT reads were positive, and in 7/84 (8%) patients, the blinded pelvic MRI reads were negative while the clinical pelvic MRI reads were positive. In 2/17 (12%) patients with metastatic BCR, the blinded PSMA PET/CT reads were negative while the clinical PSMA PET/CT reads were positive, and in 1/17 (6%) patients, the blinded pelvic MRI reads were negative while the clinical pelvic MRI reads were positive. 48% of patients underwent radiation as a next step in management, 26% underwent biopsy, 15% underwent follow-up imaging, and 11% underwent other focal or systemic therapy. Conclusions: In this retrospective, descriptive analysis, there was good agreement between PSMA PET/CT and pelvic MRI for localized BCR, although pelvic MRI may overcall lesions in the prostate and prostate bed and miss nodal metastases. For patients with metastatic BCR, PSMA PET can disclose lesions that are outside the field-of-view of pelvic MRI.

Outcomes with first-line ipilimumab and nivolumab for patients with metastatic renal cell carcinoma by number of doses.

Journal of Clinical Oncology Sahil D Doshi, Andrea Lopez Sanmiguel, Andrea Knezevic et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.540

540 Background: Ipilimumab (IPI) and nivolumab (NIVO) are standard first-line systemic therapy for patients with metastatic renal cell carcinoma (RCC). The regimen is administered in combination once every 3 weeks for 4 doses, followed by NIVO maintenance. The dose and frequency of IPI appears to correlate with treatment safety and tolerability across cancer types. Further, studies in advanced melanoma have demonstrated that the efficacy of IPI + NIVO is largely driven by the first two doses in many patients (Postow MA et al., J Clin. Oncol. 2022). We assessed outcomes with IPI + NIVO by number of doses given in patients with metastatic RCC. Methods: We conducted a retrospective study of patients with metastatic RCC at Memorial Sloan Kettering Cancer Center treated with first-line IPI + NIVO. Baseline characteristics and treatment outcomes were obtained from electronic health record review. We calculated overall survival (OS) by the Kaplan-Meier method starting at 12 weeks after initiation of combination therapy, including all patients who were still alive and being followed at that time point and excluding those who had disease progression prior to completing 4 doses. We compared survival rates at 12 and 18 months and median OS for patients who received 4 doses versus those who received fewer than 4 doses. Results: Patients with metastatic RCC treated with first-line IPI + NIVO were included (N=222); 77% were male, 85% had clear cell RCC, 48% had sarcomatoid and/or rhabdoid features, and 87% had IMDC intermediate or poor risk disease. Regarding IPI + NIVO, 145 patients (65%) received all 4 doses, 30 (14%) received 3 doses, 21 (9%) received 2 doses, and 26 (12%) received 1 dose. The most common reasons for not completing all 4 doses (77, 35%) were toxicity (57%) and disease progression (21%). All 145 patients who received 4 doses and 44 who received fewer than 4 doses for reasons other than early progression or death were included in the analysis. OS in the 4 dose and &lt;4 dose group at 18 months was 83% (95% CI: 76%, 89%) and 79% (95% CI: 63%, 88%), respectively. Conclusions: In this observational analysis, we found comparable OS rates in those patients who received all 4 doses of IPI + NIVO compared to those who received fewer than 4 doses for reasons other than disease progression, primarily toxicity. Four Doses of IPI + NIVO (N=145) Fewer Than Four Doses of IPI + NIVO, Excluding Early Disease Progression (N=44) 12-month OS (95% CI) 89% (82%, 93%) 86% (72%, 94%) 18-month OS (95% CI) 83% (76%, 89%) 79% (63%, 88%) Median OS, months (95% CI) 67.1 (40.1, NR) 82.5 (27.1, 109.3) Log-rank p value = 0.595

Mass cytometry-based deep immune cell profiling of metastatic clear cell renal cell carcinoma patients refractory to combined immune checkpoint and tyrosine kinase inhibitor therapy.

Journal of Clinical Oncology Luigi Formisano, Stefania Belli, Angela Vallefuoco et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.576

576 Background: Combination of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) improved outcomes for patients with metastatic clear cell renal cell carcinoma (mccRCC). However, some patients experience rapid disease progression. Identifying specific immune phenotypes and predictive circulating biomarkers is essential for the early detection of patients who may be refractory to ICI-TKI therapy. Methods: Serum samples and peripheral blood mononuclear cells (PBMCs) were collected from patients classified as complete responders (CR, n=4), partial responders (PR, n=10), and non-responders (NR, n=8) after 15 days (T1) and 1 month (T2) of nivolumab (ICI) and cabozantinib (TKI) therapy. Serum cytokines were analyzed using LEGENDplex, while PBMC immunophenotyping was performed using CyTOF to assess 37 immune cell populations and T cell markers related to activation, migration, and exhaustion. Results: In both responding and non-responding patients a common significant 90% reduction of PD1+TM3-CD8+ cells (p=0.0096 and p=0.0001, in CR and NR, respectively) and dendritic cells (decrease of 47% p=0.0004 in CR, 70% p=0.0059 in PR and 62% decrease p=0.0396 in NR) following therapy was observed. PD1+ Treg cells decreased significantly (93% decrease, p=0.0068) only in the CR after therapy. Additionally, CRs exhibited higher levels of exhausted PD1+ Treg cells (2.88 fold, p=0.0084) at baseline and an increased number of pro-inflammatory CD4+ Th2 cells (2 fold, p=0.0170) after one month compared to the other groups. PRs and NRs showed lower levels of natural killer cells (2.2 fold, p=0.0069), and a significant decrease of monocytes populations after therapy (45% decrease p=0.0008 in PRs, 40% decrease p=0.0012 in NRs). The CRs exhibited elevated levels of IL-23 (18 fold higher vs. NRs and 3 fold higher vs. PRs, p= 0.0094; p=0.0011) and IL-27 at baseline , and higher IL-15 and IL-18 levels post-therapy compared to the PR and NR. Kaplan-Meier plot analysis indicated that higher IL-23 levels correlated with an improved probability of PFS in all cancer patients treated with nivolumab (2.97 vs. 29.7 months in low vs. high expression cohorts; HR= 0.53 [95% CI 0.33 - 0.85], log-rank P = 0.0074). Conclusions: Our results suggest that patient’s initial immune profile might be significant predictor of treatment success and the likelihood of developing resistance.

Pathological subclassification of T3 upper tract urothelial carcinoma: Complementary evidence for existing guidelines.

Journal of Clinical Oncology Lei Zheng, Jianjun Ye, Qihao Wang et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.841

841 Background: According to the current guidelines, upper tract urothelial carcinoma (UTUC), which encroaches beyond the muscularis propria but does not invade peripheral organs or perirenal fat, is classified as pathological T3 (pT3). However, the current classification definition of pT3 fails to meet clinical needs due to the significant heterogeneity of pT3 UTUC in terms of biological features and oncological outcomes. Therefore, the aim of this study was to explore the effect of subclassifying pT3 UTUC on oncological outcomes based on a large UTUC cohort from Southwest China. Methods: Data of pathologically confirmed UTUC patients treated with radical nephroureterectomy (RNU) treatment at West China Hospital of Sichuan University from May 2003 to June 2019 were retrospectively collected. Only patients with a diagnosis of initial pT3 and complete follow-up information were included in the study. pT3 was subclassified into pT3a (defined as tumor invasion of the ureteral adventitia or renal parenchyma) and pT3b (defined as tumor invasion of the ureter or peri-pelvic fat). The primary endpoints included cancer-specific survival (CSS), overall survival (OS) and recurrence-free survival (RFS). Results: A total of 326 patients with initial pT3 UTUC were finally included. According to our proposed subclassification, 232 cases were in pT3a group and 94 cases were in pT3b group. K-M analysis showed that the patients in pT3b group had significantly worse OS, CSS and RFS than those in pT3a group. Multifactorial Cox regression analysis demonstrated that patients in pT3b group had a 1.86-fold (95% CI, 1.19-2.91) risk of death, a 1.95-fold (95% CI, 1.21-3.17) risk of disease-related death and a 1.78-fold (95% CI, 1.21-3.17) risk of disease recurrence than those in the pT3a group. After adjustment for tumor size, tumor grade and lymph node metastasis the above findings remained statistically significant. Conclusions: Based on the presence or absence of invasion of the ureter and peri-pelvic fat, our study proposes a novel pT3 subclassification, which provide physicians with invaluable insight into better stratification of pT3 UTUC patients and provide a basis for individualized treatment.

Metabolic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma.

Journal of Clinical Oncology Renee Maria Saliby, Chris Labaki, Tejas Jammihal et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.571

571 Background: Immune checkpoint inhibitors (ICI) have led to remarkable, long-lasting responses in a subset of patients with metastatic renal cell carcinoma (RCC). However, the molecular mechanisms driving these exceptional responses (ER) are not fully characterized. We previously observed that a high tertiary lymphoid structure (TLS) signature is associated with ER. Here, we explore metabolic molecular determinants that may influence ER in patients treated with ICI and VEGF inhibitors. Methods: We analyzed genomic and transcriptomic data from 357 treatment-naïve patients with advanced clear cell RCC who were given PD1/L1 and VEGF inhibitors (ICI/VEGFi) in a phase III clinical trial. Patients were categorized into three groups: (a) extreme responders (ER), including those with complete response (CR) and progression-free survival (PFS) of at least 12 months, or partial response (PR) with significant tumor shrinkage and prolonged PFS; (b) intermediate responders (IR), patients with CR or PR not meeting ER criteria; and (c) patients with progressive disease (PD). Whole exome sequencing (WES) was used to analyze somatic mutations, copy number changes, and compute clonal neoantigen load (CNL). Gene set enrichment analysis (GSEA) was performed to explore molecular pathways, and multivariate Cox proportional hazards analysis identified PFS predictors. Results: Metabolic pathway enrichment was notable in ER patients with low TLS signatures, with pathways such as peroxisome function, xenobiotic and bile acid metabolism, adipogenesis, fatty acid metabolism, and oxidative phosphorylation showing upregulation. These findings held after adjusting for tumor purity. Next, we defined a metabolic gene signature based on the enriched metabolic genes in TLS-low ER samples compared to TLS-high ER samples. ER patients with low TLS scores had significantly higher metabolic signature scores than IR (p=0.00062) and PD (p=0.00012) patients. Higher metabolic signature scores correlated with improved PFS (p=0.054) and overall survival (OS) (p=0.0037). Multivariable analysis confirmed that favorable IMDC risk (p&lt;0.001) and a high metabolic signature (p=0.01) were independent predictors of ER. Conclusions: Metabolic pathways are critical drivers of exceptional responses to ICI in RCC, especially in patients with low TLS scores. A high metabolic gene signature may serve as a predictive biomarker for ER, offering insights into new therapeutic strategies targeting metabolic reprogramming in this unique subset of patients.

OMAHA-003: A phase 3 study of CYP11A1 inhibitor opevesostat versus next-generation hormonal agent (NHA) switch in metastatic castration-resistant prostate cancer (mCRPC) after NHA and taxane-based chemotherapy.

Journal of Clinical Oncology Evan Y. Yu, Yue Song, Chris Garratt et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps286

TPS286 Background: The androgen receptor (AR) plays a pivotal role in prostate cancer pathogenesis, even after progression on androgen-directed therapies (ADT). In patients with mCRPC, activation of AR ligand binding domain (AR-LBD) somatic point mutations is a common mechanism of resistance to ADTs. Opevesostat (MK-5684; ODM-208) is an oral, nonsteroidal inhibitor of cytochrome P450 11A1 (CYP11A1), which catalyzes the first and rate-limiting step of steroid biosynthesis. By inhibiting CYP11A1, opevesostat suppresses the production of all steroid hormones and their precursors that may promiscuously activate the AR signaling pathway. Opevesostat showed antitumor activity in patients with heavily pretreated mCRPC, and in those with AR-LBD mutations, in the phase 1/2 CYPIDES trial (Fizazi et al. NEJM Evid. 2024). The randomized, open-label, phase 3 OMAHA-003 study (NCT06136624) is evaluating the efficacy and safety of opevesostat versus NHA switch in patients with mCRPC who received NHA and taxane-based chemotherapy. Methods: Eligible patients havemCRPC (unselected for AR-LBD mutations) that progressed on ADT ≤6 months of screening and during/after treatment with 1 NHA or 1-2 taxane-based chemotherapies. Approximately 1200 patients (300 with, 900 without AR-LBD mutations) will be randomly assigned 1:1 to opevesostat 5 mg PO BID (+ dexamethasone 1.5 mg and fludrocortisone 0.1 mg QD) or enzalutamide 160 mg PO QD (if prior abiraterone) or abiraterone acetate 1000 mg PO QD (if prior enzalutamide/darolutamide/apalutamide). Primary endpoints are radiographic progression-free survival per Prostate Cancer Working Group 3 (PCWG3)-modified RECIST v1.1 by blinded independent central review (BICR) and overall survival in patients with AR-LBD mutation-positive and -negative disease, separately. Secondary endpoints include time to initiation of first subsequent anticancer therapy or death; objective response rate and duration of response per PCWG3-modified RECIST v1.1 by BICR; and safety. Enrollment is ongoing. Clinical trial information: NCT06136624 .

Frequency and impact of a genome-wide homologous recombination deficiency signature (HRDsig+) on the genomic landscape of clinically advanced urothelial bladder carcinoma (CAUBC).

Journal of Clinical Oncology Michael Basin, Andrea Necchi, Roger Li et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.845

845 Background: CAUBC (metastatic and surgically incurable advanced UBC) is a challenging with significant need for improvement in systemic therapies. We aimed to explore HRD sig status and related biomarkers, including other GA, to generate hypothesis and inform clinical trial designs for these patients. Methods: 8825 cases of CAUBC underwent comprehensive genomic profiling (CGP) to examine all classes of genomic alterations (GA). MSI high status, tumor mutation burden (TMB) levels, genomic ancestry and trinucleotide mutational signatures were determined from the sequencing data. HRDsig status was calculated using a broad set of genome-wide copy number features. PD-L1 was determined by IHC using the Dako 22C3 tumor proportional score (TPS) system. Results were compared using the Fisher exact system with the Benjamini-Hochberg adjustment to correct for false discovery. Results: 387 (4.4%) of CAUBC cases featured a positive HRDsig status (HRDsig+). The median age (62-63) was similar in the HRDsig+ and HRDsig- groups and both groups were predominantly male (75-77%). The GA/tumor frequencies were similar (5-6). MSI-high status was extremely low in both groups (0.8% vs 0%). The median TMB (10 vs 6.3; P&lt;.0001) and frequency of TMB &gt; 10 mutations/Mb (50.9% vs 34.8%; P=0.016) was higher in the HRDsig+. Trinucleotide mutational signature distribution, PD-L1 low (1-49% TPS) and PD-L1 high (≥50% TPS) expression were similar in both groups. As anticipated, GA in genes associated with HRD including BRCA1 (9.0% vs 1.6%; P&lt;0.0001), BRCA2 (17.1% vs 2.5%; P&lt;0.0001), ATM (9.6% vs 5.3%; P=0.0003) and RAD21 (8.5% vs 3.4%; P&lt;0.0001) were more frequent in the HRDsig+ cases. In the HRDsig- group, 83.7%/87.0% of BRCA1 / BRCA2 mutated CAUBC were mono-allelic, likely non-driver GA, respectively. FGFR3 GA were significantly more frequent in the HRDsig- CAUBC (18.1% vs 10.9%; P=0.001). GA in ERBB2 (17.8-18.5%) and ERBB3 (6.2-7.8%) were similar in both groups. MTOR pathway related mutations, including PTEN (4.5-6.2%) and PIK3CA (18.6-21.7%) were similar in both groups. GA in TERT were more frequent in the HRDsig- group (78.9% vs 57.6%; P&lt;0.0001) and GA in TP53 were more frequent in the HRDsig+ cases (72.1% vs 60.5%; P&lt;0.0001). Conclusions: With a 4.4% frequency, HRDsig+ status is a relatively uncommon biomarker in CAUBC. This finding may inform clinical trial designs, for example with PARP inhibitors and other ‘HRD-targeting’ agents. Limitations include the retrospective nature, potential selection bias and lack of clinical outcomes annotation. Genomic differences between HRDsig- and HRDsig+ CAUBC groups. CAUBC HRDsig- CAUBC HRDsig+ P value EUR Ancestry 85.2% 78.6% 0.003 ATM 5.3% 9.6% 0.003 BRCA1 1.6% 9.0% &lt;.0001 BRCA2 2.5% 17.1% &lt;.0001 FGFR3 18.1% 10.9% 0.001 RAD21 3.4% 8.5% &lt;.0001 TP53 60.5% 72.1% &lt;.0001 RB1 2.7% 5.4% &lt;.0001 TMB≥10 mut/Mb 34.8% 50.9% 0.016

CORE-008: A phase 2, multi-arm, multi-cohort, open-label study to evaluate intravesical cretostimogene grenadenorepvec in participants with high-risk non-muscle invasive bladder cancer.

Journal of Clinical Oncology Trinity Bivalacqua, Siamak Daneshmand, Neal D. Shore et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps901

TPS901 Background: Treatment for patients with High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) consists of Transurethral Resection of Bladder Tumor (TURBT) followed by intravesical Bacillus Calmette–Guérin (BCG). Despite high initial response rates, over 50% of patients will recur and 20-40% are at risk for progression. Treatment of HR NMIBC is challenged by the BCG shortage, thus there exists a need for clinically effective, well-tolerated, and readily available treatment options for patients with HR NMIBC. Cretostimogene grenadenorepvec is an oncolytic immunotherapy with a dual mechanism of action. It selectively replicates and lyses bladder cancer cells with Retinoblastoma (Rb)-E2F pathway alterations. The subsequent release of virus- and tumor- specific antigens initiate antitumor immune activation amplified by the GM-CSF transgene, a potent cytokine. Cretostimogene received both Fast Track and Breakthrough Therapy Designations by the US FDA for the BCG-Unresponsive HR NMIBC with CIS indication. Given the strength of these data, the CORE-008 clinical trial ( NCT06567743 ) was developed as a Phase 2, multi-arm, multi-cohort trial to further evaluate the safety and efficacy of cretostimogene in patients with HR NMIBC. Methods: Eligibility criteria include pathologic confirmation of HR NMIBC as defined by the American Urologic Association (AUA) Guidelines. Cohort A (BCG-naive) is comprised of CIS +/- HG Ta/T1 participants who have not received prior BCG. Cohort B (BCG-exposed) will consist of CIS +/- HG Ta/T1 or papillary-only patients who have received prior BCG, and recurred either immediately after induction therapy (BCG-resistant) or recurred at a delayed timepoint, after adequate or inadequate BCG. Intravesical cretostimogene will be instilled in combination with n-dodecyl-β-D-maltoside (DDM), an excipient, that enhances adenoviral delivery, for six weekly doses during the induction phase, followed by three weekly maintenance cycles quarterly through month 12, then every six months through month 36. Re-induction is permitted. The primary endpoint for the CIS population is Complete Response (CR) at any time. High-Grade Event-Free Survival is the primary endpoint for papillary-only participants. Secondary endpoints will include Duration of Response, all-cause Event-Free Survival, Bladder Cancer Specific Survival, Radical Cystectomy Free Survival, and safety. Exploratory outcome measures include Health-Related Quality of Life, Overall survival, and biomarker assessments. Additional HR NMIBC cohorts are under development. Multiple clinical sites have been identified and Cohort B has received collaborative support from the Society of Urologic Oncology-Clinical Trials Consortium. Clinical trial information: NCT06567743 .

Evaluating molecular alteration profiles to distinguish intraductal carcinoma of the prostate.

Journal of Clinical Oncology Harshitha Reddy Dudipala, Shayan Nazari, Isabela Werneck da Cunha et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.407

407 Background: Intraductal carcinoma of the prostate (IDC-P) is an intra-acinar and/or intraductal neoplastic epithelial proliferation that is a distinct entity in the 2016 WHO classification system for prostate cancer. Clinically, it is associated with higher grade tumors and a more aggressive disease course with a high risk of local recurrence and distant metastasis. However, the molecular underpinnings of IDC-P are not well elucidated. We present comprehensive molecular profiling data from the largest cohort of IDC-P cases reported to date, with direct comparison to a matched cohort of adenocarcinoma cases. Methods: We identified radical prostatectomy (RP) cases from Caris Life Sciences database, classified as prostatic adenocarcinoma with Grade Group 4-5 or had the words “cribriform”, “necrosis”, or “intraductal” in the pathology report, for which imaging files were available. Digitized H&amp;E slides underwent central pathology review by a board-certified genitourinary pathologist (IW) to identify the presence of IDC-P according to the 2022 WHO classification. Cases with IDC-P were compared to cases without IDC-P on central review or lacked reference to “cribriform”, “necrosis”, or “intraductal” in the RP pathology report (non-IDC-P). Prostatic tumor specimens were sequenced at Caris Life Sciences via NextGen DNA Seq (592 gene panel or whole exome) and RNA Seq (whole transcriptome). Results: 4,880 cases were identified, of which 176 were confirmed to have IDC-P with median age of 63.5 years. 43% (76/176) of IDC-P cases were Grade Group 5 and 99% (175/176) were Grade Group 3 or higher. Compared to non-IDC-P cases, the IDC-P cohort had significantly more mutations in MUTYH (4.5% vs. 1.4%, p &lt;0.01), FANCA (2.7% vs. 0.5%, p &lt;0.01), NBN (2.5% vs. 0.6%, p &lt;0.05), and MTOR (0.6% vs. 0.1%, p &lt;0.05), and fewer alterations in AR (0% vs. 0.7%, p &lt;0.01) and AR-V7 splice variants (5.5% vs. 6.2%, p &lt;0.001). IDC-P tumors were enriched for DLL3 and CEACAM5 expression with lower expression of STEAP1, TROP2, ERBB2, and B7-H3 compared to non-IDC-P. Patients with IDC-P had significantly higher neuroendocrine prostate cancer (NEPC) signature scores, with similar AR signature scores compared to non-IDC-P. The tumor microenvironment of IDC-P tumors had significantly higher cell fractions of M2 macrophages and regulatory T cells, and fewer dendritic cells. Conclusions: Our findings demonstrate that IDC-P possesses a distinct molecular profile and immunologic phenotype. Specifically, we observed an increased prevalence of DNA repair alterations, including in the MUTYH gene. Furthermore, IDC-P showed an increased NEPC signature and a more immunosuppressive phenotype. This information is important for developing personalized treatment strategies for histologically distinct prostate cancer subsets.

Assessment of the proficiency of ChatGPT-4o in an image-based robot-assisted radical prostatectomy scenario.

Journal of Clinical Oncology Jiakun Li, Jing Zhao, Zeqi Wang et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.423

423 Background: Surgery is a process that heavily relies on complex visual information. Many AI-based surgical teaching and assistance applications have emerged. However, the application of the newly released ChatGPT-4o in surgical contexts remains unexplored. This study aims to investigate the ability of ChatGPT-4o in analyzing and recognizing anatomical structures, surgical procedures, and operational precautions based on image information in a surgical context. Utilizing screenshots from robot-assisted radical prostatectomy videos sourced from the internet. Methods: We developed a test comprising 77 images and 65 questions, with a total score of 100 points. The test includes sections on anatomical structures, surgical procedures, and operational precautions. We sequentially input the questions into the ChatGPT-4o model and employed strategies to enhance its performance during the test. A passing score was set at 60 points or above, and an excellent score at 80 points or above. Results: ChatGPT-4o achieved a score of 68, surpassing the passing threshold. The accuracy for non-image questions was higher than for image-based questions (85.71% vs. 58.46%, χ² = 7.78, p = 0.005), and questions with fewer images had a higher accuracy than those with multiple images (71.11% vs. 30.00%, p &lt; 0.001). Furthermore, we found ChatGPT-4o performed differently in recognizing different structures, with the highest accuracy for questions involving muscle and fascia (100%) and the lowest for those involving nerve and vessel structures (33.33%). Conclusions: ChatGPT demonstrated commendable abilities in image recognition and problem analysis in surgical contexts. We hope that the results of this study will contribute to future applications of ChatGPT in AI-assisted surgical teaching and assistance.

Large language models (LLMs) for inferring genomic characteristics and facilitating genomic literacy in prostate cancer (PCa) patients.

Journal of Clinical Oncology Syed Arsalan Ahmed Naqvi, Umair Ayub, Muhammad Ali Khan et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.261

261 Background: Clinicians use next-generation sequencing (NGS) to tailor targeted treatments for PCa patients. However, the results are often available in unstructured formats and are saturated with technical jargon, making them inaccessible for patients. Therefore, we aimed to assess the efficacy of LLMs to accurately extract genomic characteristics from unstructured reports and generate patient-friendly summaries for ease of variant interpretation in PCa patients. Methods: This retrospective study included patients with PCa who underwent NGS from 2023-2024. The GPT4 model was utilized using structured zero-shot prompts to extract genomic characteristics from unstructured reports in a non-decomposed manner. Prompt development was conducted iteratively using a 2% random sample of the dataset. Genomic characteristics ascertained by LLM were assessed against held out vendor-curated test dataset for evaluation. Performance was assessed using weighted evaluation metrics (precision, recall, and F1-score). Additionally, the extracted variables were organized using rule-based criterion and presented as a separate prompt to GPT4 to generate summaries for interpretation at the level of each biologically relevant variant. Mean Flesch-Kincaid scores and Vocd-D statistic with standard deviations were computed to assess readability and lexical diversity of LLM-generated variant interpretation summaries. Results: A total of 331 patients (370 NGS reports) were included in the study. Evaluation on the held-out test dataset (Table) showed that the weighted average precision ranged from 80% for extracting tumor mutational burden to 100% for extracting the CtDNA fraction from unstructured reports. The weighted average recall ranged from 85% for extracting CtDNA tumor fraction to 99% for ascertaining variant/alteration. The weighted average F1-scores varied from 0.83 for extracting tumor mutational burden to 1.0 for extracting specimen site from NGS reports. The mean Flesch-Kincaid score was 8.29 ± 1 indicating average/standard readability ease. The mean Vocd-D statistic was 7.55 ± 1 indicating focused summaries, however, with limited lexical diversity. Conclusions: This study suggests that large language models can effectively extract genomic characteristics from unstructured reports and can potentially improve genomic literacy among prostate cancer patients by providing easy-to-interpret variant summaries. However, targeted prompting may be required to increase lexical diversity for improved engagement. Performance across different genomic characteristics. Category Precision Recall F1-Score Altered gene 0.86 0.97 0.89 Variant/alteration type 0.98 0.99 0.98 Variant allele fraction 0.96 0.96 0.96 Test name/type 1 0.99 1 Specimen site 1 0.99 1 Tumor mutational burden 0.8 0.93 0.83 CtDNA tumor fraction 1 0.85 0.92 MSI status 0.99 0.97 0.98